For information on Merck’s changes to non-GAAP reporting please click here
To learn more about the pending spinoff leading up to the Investor Day, please click here.
Merck & Co., Inc., Kenilworth, NJ, USA (the company) is known as Merck in the United States and Canada and MSD outside the United States and Canada.
The company is traded on the New York Stock Exchange (NYSE) and the Paris Stock Exchange under the ticker “MRK”.
The company’s principal executive offices are located at: 2000 Galloping Hill Road Kenilworth, NJ, USA 07033
The company’s fiscal year ends on December 31st of each year.
PricewaterhouseCoopers LLP Florham Park, NJ, USA
Yes, please visit our Dividend History page here to see our historical dividends paid.
Shares can be purchased through a stockbroker of your choice or by contacting our transfer agent, EQ Shareowner Services.
Merck Shareowner Services EQ Shareowner Services 1110 Centre Pointe Curve Suite 101 Mendota Heights, MN, USA 55120-4100
Questions regarding stock holdings, certificate replacement/transfer, dividends and address changes should be directed to our transfer agent, EQ Shareowner Services. You can reach them at 800-522-9114 or at their website here
The best way to reach the company’s investor relations department is by email at
investor_relations@merck.com
Typically, the company’s annual meeting is held in May, but the date is subject to change at the discretion of the Board of Directors.
Yes. Please contact our transfer agent, EQ Shareowner Services, for more information. Contact information is provided above.
Monday - Friday, 8:30 a.m - 4:00 p.m., ET
908 740-1 INV (908 740-1468)
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.